Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 11

Scientists are designing simplified biological systems, aiming to construct synthetic cells and better understand life’s mechanisms.

One of the most fundamental questions in science is how lifeless molecules can come together to form a living cell. Bert Poolman, Professor of Biochemistry at the University of Groningen, has been working to solve this problem for two decades. He aims to understand life by trying to reconstruct it; he is building simplified artificial versions of biological systems that can be used as components for a synthetic cell.

His work was detailed in two new papers published in Nature Nanotechnology and Nature Communications. In the first paper, he describes a system for energy conversion and cross-feeding of products of this reaction between synthetic cells, while he describes a system for concentrating and converting nutrients in cells in the second paper.

Read more | >

Novel magnetic nanodiscs could provide a much less invasive way of stimulating parts of the brain, paving the way for stimulation therapies without implants or genetic modification, MIT researchers report.

The scientists envision that the tiny discs, which are about 250 nanometers across (about 1/500 the width of a human hair), would be injected directly into the desired location in the brain. From there, they could be activated at any time simply by applying a magnetic field outside the body. The new particles could quickly find applications in biomedical research, and eventually, after sufficient testing, might be applied to clinical uses.

The development of these nanoparticles is described in the journal Nature Nanotechnology, in a paper by Polina Anikeeva, a professor in MIT’s departments of Materials Science and Engineering and Brain and Cognitive Sciences, graduate student Ye Ji Kim, and 17 others at MIT and in Germany.

Read more | >

In an incredible feat that redefines biological boundaries, scientists have successfully engineered animal cells capable of photosynthesis.

This breakthrough, led by Professor Sachihiro Matsunaga at the University of Tokyo, could transform medical research and aid in advancing lab-grown meat production.

Photosynthesis, traditionally exclusive to plants, algae, and certain bacteria, is a process that uses sunlight, water, and carbon dioxide to produce oxygen and sugars – essentially “feeding” the organism.

Read more | >

RegenxBio, a publicly-traded biotech firm, released data this week from a Phase 2 clinical trial designed to test its leading genetic therapy product in patients with bilateral wet age-related macular degeneration (AMD). AMD is characterized by abnormal growth of blood vessels in the retina, and is a leading cause of loss of vision in elderly populations globally.

ABBV-RGX-314, developed in collaboration with AbbVie, offers the potential of a one-time treatment for wet AMD and other retinal conditions, including diabetic retinopathy. This is in contrast to existing treatments which rely on repeated intraocular injections of drugs that inhibit a protein known as Vascular Endothelial Growth Factor (VEGF), a protein responsible for the formation of new retinal blood vessels.

The ABBV-RGX-314 therapy is based on a an AAV8 viral vector as a delivery system. The AAV8 platform has been genetically engineered to encode an antibody that can inhibit VEGF for the long-term.

Read more | >

The researchers’ recently published study describes a way to re-activate apoptosis in mutated cells, which would amount to forcing cancer to self-destruct through a bioengineered, bonding molecule.

Gerald Crabtree, one of the study’s authors and a professor of development biology, said he had the idea while hiking through Kings Mountain, California, during the pandemic period. The new compound would have to bind two proteins which already exist in the cancerous cells, turning apoptosis back on and making the cancer kill itself.

“We essentially want to have the same kind of specificity that can eliminate 60 billion cells with no bystanders,” Crabtree said, so that no cell gets destroyed if it isn’t the proper target of this new killing mechanism. The two proteins in question are known as BCL6, an oncogene which suppresses apoptosis-promoting genes in the B-cell lymphoma, and CDK9, an enzyme that catalyzes gene activation instead.

Read more | >

“Badass”. That was the word Harvard University neuroscientist Steve Ramirez used in a Tweet to describe research published online by fellow neuroscientist Ali Güler and colleagues in the journal Nature Neuroscience last March. Güler’s group, based at the University of Virginia in the US, reported having altered the behaviour of mice and other animals by using a magnetic field to remotely activate certain neurons in their brains. For Ramirez, the research was an exciting step forward in the emerging field of “magnetogenetics”, which aims to use genetic engineering to render specific regions of the brain sensitive to magnetism – in this case by joining proteins containing iron with others that control the flow of electric current through nerve-cell membranes.

By allowing neurons deep in the brain to be switched on and off quickly and accurately as well as non-invasively, Ramirez says that magnetogenetics could potentially be a boon for our basic understanding of behaviour and might also lead to new ways of treating anxiety and other psychological disorders. Indeed, biologist Kenneth Lohmann of the University of North Carolina in the US says that if the findings of Güler and co-workers are confirmed then magnetogenetics would constitute a “revolutionary new tool in neuroscience”

The word “if” here is important. In a paper posted on the arXiv preprint server in April last year and then published in a slightly revised form in the journal eLife last August, physicist-turned-neuroscientist Markus Meister of the California Institute of Technology laid out a series of what he describes as “back-of-the-envelope” calculations to check the physical basis for the claims made in the research. He did likewise for an earlier magnetogenetics paper published by another group in the US as well as for research by a group of scientists in China positing a solution to the decades-old problem of how animals use the Earth’s magnetic field to navigate – papers that were also published in Nature journals.

Read more | >

Bioengineers propose “electro-agriculture,” a method that replaces photosynthesis with a solar-powered reaction converting CO2 into acetate, potentially reducing U.S. agricultural land needs by 94% and supporting controlled indoor farming.

Initial experiments focus on genetically modified acetate-consuming plants like tomatoes and lettuce, with potential future applications in space agriculture.

Revolutionary Electro-Agriculture

Read more | >

Discovery advances development of new therapeutic options for cancer and other diseases. A research team led by the University of California, Irvine has engineered an efficient new enzyme that can produce a synthetic genetic material called threose nucleic acid. The ability to synthesize artificial chains of TNA, which is inherently more stable than DNA, advances the discovery of potentially more powerful, precise therapeutic options to treat cancer and autoimmune, metabolic and infectious diseases.

A paper recently published in Nature Catalysis describes how the team created an enzyme called 10–92 that achieves faithful and fast TNA synthesis, overcoming key challenges in previous enzyme design strategies.

Inching ever closer to the capability of natural DNA synthesis, the 10–92 TNA polymerase facilitates the development of future TNA drugs.

Read more | >

The acetate would then be used to feed plants that are grown hydroponically. The method could also be used to grow other food-producing organisms, since acetate is naturally used by mushrooms, yeast, and algae.

“The whole point of this new process to try to boost the efficiency of photosynthesis,” says senior author Feng Jiao, an electrochemist at Washington University in St. Louis. “Right now, we are at about 4% efficiency, which is already four times higher than for photosynthesis, and because everything is more efficient with this method, the CO2 footprint associated with the production of food becomes much smaller.”

To genetically engineer acetate-eating plants, the researchers are taking advantage of a metabolic pathway that germinating plants use to break down food stored in their seeds. This pathway is switched off once plants become capable of photosynthesis, but switching it back on would enable them to use acetate as a source of energy and carbon.

Read more | >